Press release
Orphan Drugs Market Growing $169 Billion By 2022
For More Info, Get Sample : http://bit.ly/2zcuCox
Orphan drugs are used to treat rare (orphaned) diseases prevalent in a very small patient pool. Hence, the pharmaceutical industry takes little interest in their development. Moreover, their development requires high cost and the chances of returns on investment are comparatively less when compared to non-orphan drugs. These drugs treat different rare diseases, such as non-Hodgkin lymphoma, acute myeloid leukemia, cystic fibrosis, and others.
Conducive government regulations and market exclusivity for orphan drugs drives the global orphan drugs market. In addition, surge in prevalence of rare diseases and rise in investment in research, drug development, and innovation supplement the market growth. However, limited patient pool for clinical trials & product marketing and high treatment costs per patient impede the market growth. Furthermore, growth in novel indications for known orphan drugs and untapped emerging markets offer lucrative opportunities for the market players.
The orphan drugs market is segmented based on disease type, indication, and geography. Based on disease type, the market is divided into oncologic diseases, metabolic diseases, hematologic and immunologic diseases, infectious diseases, neurologic diseases, and other rare diseases. In the orphan drugs disease type segment, oncologic diseases occupied dominant share in 2015, and the segment is expected to maintain this trend during the forecast period. This is attributed to the array of different forms of rare cancers, such as leukemia, myeloma, angiosarcoma, and others prevalent in the patient population.
Based on indication, this market is classified into non-Hodgkin lymphoma, acute myeloid leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, multiple myeloma, Duchenne muscular dystrophy, Graft vs host disease, renal cell carcinoma, and others. The non-Hodgkin lymphoma was the highest revenue contributor in 2015, while renal cell carcinoma is anticipated to grow at the highest rate. The growth for this segment is due to increase in investment in R&D throughout the world along with surge in awareness about kidney cancer.
Enquire About Report : http://bit.ly/2hKgETv
Geographically, this market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in the orphan drugs market in 2015, and is expected to retain its dominance throughout the forecast period. This is primarily attributed to the higher buying power, availability, accessibility, and treatment options that favor the utilization of orphan drugs in this region. There is also an increase in product approvals for different pharmaceutical products designated as orphan drugs by the U.S. Food and Drug Administration (FDA), which fosters the market growth. However, Asia-Pacific is expected to emerge as a lucrative area with maximum growth potential, owing to the improvement in R&D facilities, available disposable income, and rapidly developing economic conditions.
Product development is the key strategy adopted by market players. The report provides a comprehensive analysis of the key players that operate in the global orphan drugs market.
KEY PLAYERS PROFILED
• AbbVie Inc.
• Aegerion Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson.
• Novartis AG
• Pfizer Inc.
• Sanofi
KEY MARKET BENEFITS
• The study provides an in-depth analysis of the global orphan drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
• The report presents quantitative analysis of the market from 2014 to 2022 to enable stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the market based on indications assists in understanding the trends in the industry.
• Key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.
Also Request For Discount : http://bit.ly/2hUsQVG
KEY MARKET SEGMENTS
By Disease Type
• Oncologic Diseases
• Metabolic Diseases
• Hematologic and Immunologic Diseases
• Infectious Diseases
• Neurologic Diseases
• Other Rare Diseases
By Indication
• Non-Hodgkin Lymphoma
• Acute Myeloid Leukemia
• Cystic Fibrosis
• Glioma
• Pancreatic Cancer
• Ovarian Cancer
• Multiple Myeloma
• Duchenne Muscular Dystrophy
• Graft vs Host Disease
• Renal Cell Carcinoma
• Others
By Geography
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• Australia
• India
• South Korea
• Taiwan
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Turkey
• Saudi Arabia
• South Africa
• Rest of LAMEA
Other players in the value chain include (profiles not included in the report)
• Bayer HealthCare Pharmaceuticals Inc
• Vertex Pharmaceuticals
• Merck & Co., Inc.,
• Alexion Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• Amgen Inc.
• Biogen Idec
• Actelion Pharmaceuticals Ltd
• AstraZeneca plc
• Janssen Biotech, Inc.
Table Of Content
• CHAPTER 1 INTRODUCTION
• CHAPTER 2 EXECUTIVE SUMMARY
• CHAPTER 3 MARKET OVERVIEW
• CHAPTER 4 ORPHAN DRUGS MARKET, BY DISEASE TYPE
• CHAPTER 5 ORPHAN DRUGS MARKET, BY INDICATION
• CHAPTER 6 ORPHAN DRUGS MARKET, BY GEOGRAPHY
• CHAPTER 7 COMPANY PROFILES
About Us
We have a large database of quality and precise market research reports that will be very beneficial for your organization. Reports that we sell our authentic in nature and from reputed publishers, hence it can definitely help you with your growth opportunities. Research Beam will always make sure to bring most ethical and high-quality reports. We value your relationship with us and look forward to a long term relation.
Contact Us
Global Head Quarters
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
+1 (800) 910-6452
help@researchbeam.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Orphan Drugs Market Growing $169 Billion By 2022 here
News-ID: 828845 • Views: …
More Releases from Research Beam Market
Blood Plasma Derivatives Market Growing With $44,333 Million At A CAGR of 9.3% F …
Blood plasma is liquid component of blood where the blood cells are suspended. It contains dissolved proteins (albumins, globulins, and fibrinogen), clotting factors, hormones, and electrolytes. Plasma maintains the blood pressure and helps in exchange of important minerals such as sodium and potassium to maintain the pH balance in the body. Plasma derivatives are products that are manufactured from human plasma by plasma fractionation techniques. These derivatives include albumin, factor…
Holter ECG Monitoring Market Growing $418.3 Million By 2023
Holter monitors are devices that allow prolonged monitoring of heart rhythm from a few days to several months, enabling the detection of infrequent arrhythmias in patients. In addition, holter monitors help identify ventricular tachycardia (VT) in patients with recognized risk of sudden cardiac death. Portability of holter monitors significantly propel the market growth as they can be easily worn by the patients to record heart activity for a certain period…
Intermittent Catheters Market Reach $2,950.7 Million By 2023
The global intermittent catheters market was valued at $1,655.5 million in 2016, and is expected to reach $2,950.7 million by 2023 with a CAGR of 8.7% during the forecast period. Intermittent catheter is a disposable medical device, which is used to drain the urinary bladder when an individual is unable to do it naturally. Intermittent catheter consists of a drainage bag that assists to capture the urine. These catheters are…
Continuous Glucose Monitoring Systems Market Registering A CAGR Of 22.9% By 2024
Continuous glucose monitoring (CGM) is one of the latest technological advancements in the field of diabetes management. CGM system is a type of glucose monitoring device that functions by inserting a biosensor through transcutaneous or subcutaneous route. The embedded sensor measures the glucose levels in interstitial fluid or blood, and transmits the information using a transmitter to a receiver/monitor for displaying the results. These systems play an integral role in…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
